Insulin Delivery Method and Admission for Glycemic Control in Pregnant Women with Type 1 Diabetes Mellitus

Abstract

Objective To determine if there was a difference in glycemic control admissions or perinatal outcomes in women with type 1 diabetes mellitus (DM) treated with multiple daily injections (MDIs) versus continuous subcutaneous insulin infusion (CSII).

Materials and Methods This was a retrospective cohort study of women with type 1 DM with a singleton gestation who delivered between 2006 and 2014 at a tertiary hospital and received care at a dedicated DM clinic. Women who used MDI were compared with those who used CSII. The primary outcome was glycemic control admission during pregnancy. Secondary outcomes included adverse perinatal outcomes.

Results There were a total of 156 women; 107 treated with MDI and 49 with CSII. Women treated with MDI had higher rates of glycemic control admissions versus those treated with CSII (68.2 vs. 30.6%, p < 0.001). Adjusting for age, ethnicity, public insurer, duration of DM, first recorded hemoglobin A1c (HbA1c), and DM comorbidities, the likelihood of admission remained higher in women on MDI versus CSII (AOR 5.9 [1.7–20.6]). Women treated with MDI had higher rates of postprandial hypoglycemia. Other perinatal outcomes were similar between the groups.

Conclusion Women with type 1 DM treated with MDI were more likely to have glycemic control admissions and postprandial hypoglycemia than those treated with CSII.

Keywords

type 1 diabetes mellitus - CSII - glycemic control - continuous subcutaneous insulin infusion - multiple daily injections - insulin - pregnancy

• References

• 1 Al-Agha R, Firth RG, Byrne M. , et al. Outcome of pregnancy in type 1 diabetes mellitus (T1DMP): results from combined diabetes-obstetrical clinics in Dublin in three university teaching hospitals (1995-2006). Ir J Med Sci 2012; 181 (01) 105-109
• 2 Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ 2004; 328 (7445): 915
• 3 Kitzmiller JL, Block JM, Brown FM. , et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care 2008; 31 (05) 1060-1079
• 4 Casson IF, Clarke CA, Howard CV. , et al. Outcomes of pregnancy in insulin dependent diabetic women: results of a five year population cohort study. BMJ 1997; 315 (7103): 275-278
• 5 McElvy SS, Miodovnik M, Rosenn B. , et al. A focused preconceptional and early pregnancy program in women with type 1 diabetes reduces perinatal mortality and malformation rates to general population levels. J Matern Fetal Med 2000; 9 (01) 14-20
• 6 Gabbe SG, Graves CR. Management of diabetes mellitus complicating pregnancy. Obstet Gynecol 2003; 102 (04) 857-868
• 7 Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010; (01) CD005103
• 8 Roze S, Smith-Palmer J, Valentine W, de Portu S, Nørgaard K, Pickup JC. Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review. Diabet Med 2015; 32 (11) 1415-1424
• 9 Farrar D, Tuffnell DJ, West J, West HM. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 2016; (06) CD005542
• 10 Nachum Z, Ben-Shlomo I, Weiner E, Ben-Ami M, Shalev E. Diabetes in pregnancy: efficacy and cost of hospitalization as compared with ambulatory management--a prospective controlled study. Isr Med Assoc J 2001; 3 (12) 915-919
• 11 Schneider JM, Curet LB, Olson RW, Shay G. Ambulatory care of the pregnant diabetic. Obstet Gynecol 1980; 56 (02) 144-149
• 12 Mendez-Figueroa H, Maggio L, Dahlke JD. , et al. Treatment of severe insulin resistance in pregnancy with 500 units per milliliter of concentrated insulin. Obstet Gynecol 2013; 122 (01) 99-104
• 13 American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists' task force on hypertension in pregnancy. Obstet Gynecol 2013; 122 (05) 1122-1131
• 14 Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr 2013; 13: 59
• 15 Botta RM, Sinagra D, Angelico MC, Bompiani GD. Comparison of intensified traditional insulin therapy and micropump therapy in pregnant women with type 1 diabetes mellitus [Article in Italian]. Minerva Med 1986; 77 (17) 657-661
• 16 Carta Q, Meriggi E, Trossarelli GF. , et al. Continuous subcutaneous insulin infusion versus intensive conventional insulin therapy in type I and type II diabetic pregnancy. Diabete Metab 1986; 12 (03) 121-129
• 17 Mello G, Biagioni S, Ottanelli S. , et al. Continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) of rapid-acting insulin analogues and detemir in type 1 diabetic (T1D) pregnant women. J Matern Fetal Neonatal Med 2015; 28 (03) 276-280
• 18 Nosari I, Maglio M, Lepore G, Cortinovis F, Pagani G. Is continuous subcutaneous insulin infusion more effective than intensive conventional insulin therapy in the treatment of pregnant diabetic women?. Diabetes Nutr Metab 1993; 6 (01) 33-37
• 19 Gabbe SG, Holing E, Temple P, Brown ZA. Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. Am J Obstet Gynecol 2000; 182 (06) 1283-1291
• 20 Yee LM, Niznik CM, Simon MA. Examining the role of health literacy in optimizing the care of pregnant women with diabetes. Am J Perinatol 2016; 33 (13) 1242-1249
• 21 Brooten D, Kaye J, Poutasse SM. , et al. Frequency, timing, and diagnoses of antenatal hospitalizations in women with high-risk pregnancies. J Perinatol 1998; 18 (05) 372-376
• 22 St Charles M, Lynch P, Graham C, Minshall ME. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective. Value Health 2009; 12 (05) 674-686